Vinpocetine

1 tablet contains:

active substance:

vinpocetine

Vinpocetine has a vasodilating, antihypoxic, antiplatelet effect. It inhibits phosphodiesterase and increases the content of cyclic adenosine monophosphate in the cells, which leads to a decrease in the calcium content in the cytoplasm of smooth muscle cells and the relaxation of myofibrils. Expands the blood vessels of the brain, enhances blood flow, mainly in ischemic areas, improves the supply of oxygen to the brain.

It promotes glucose utilization and increases the level of catecholamines in the central nervous system, stimulates the metabolism of norepinephrine and serotonin in the brain tissues. Reduces platelet aggregation, blood viscosity, increases the deformability of red blood cells and normalizes venous outflow against the background of a decrease in the resistance of cerebral vessels.

Systemic blood pressure decreases slightly. In the elderly and senile age, the sensitivity of the cerebral vessels to the relaxing effect of Vinpocetine increases, which is due to the sensitization of the adenylate cyclase system - cyclic adenosine monophosphate during aging.

Pharmacokinetics

Quickly absorbed from the gastrointestinal tract, bioavailability of about 60%. The maximum concentration in plasma is reached after 1 hour. It easily penetrates the histohematological barriers (including the blood-brain barrier). The elimination half-life is about 5 hours.

- acute (if parenteral administration is not possible) and chronic forms of cerebrovascular insufficiency (including acute and residual stages of stroke, transient ischemic attacks, encephalopathy, dementia after cerebrovascular disorders);

- vascular diseases of the retina and / or choroid (due to atherosclerosis, angiospasm, thrombosis); degenerative changes in the macula caused by atherosclerosis or angiospasm; secondary glaucoma (due to vascular obstruction);

- age-related vascular or toxic (drug) hearing impairment, Meniere's disease, dizziness of labyrinth origin;
- vegetative manifestations of menopausal syndrome.

Vinpocetine is contraindicated in pregnancy and lactation (breastfeeding).

- Severe heart rhythm disturbances;
- IHD (severe course);
- acute stage of hemorrhagic stroke;
- pregnancy;
- lactation (breastfeeding);
- Hypersensitivity to the drug.

From the cardiovascular system: lowering blood pressure, tachycardia, extrasystole, slowing down intraventricular conduction.

With the use of Vinpocetine against the background of heparin therapy, the risk of developing hemorrhagic complications increases.

Inside, 1 to 2 tablets 3 times a day for 2 months.

Before discontinuing the drug, the dosage should be gradually reduced.

Repeated courses 2 to 3 times a year are possible.

Currently, cases of overdose of the drug Vinpocetine have not been reported.

Treatment: gastric lavage, intake of activated carbon; if necessary, carry out symptomatic therapy.

With the use of Vinpocetine against the background of heparin therapy, the risk of developing hemorrhagic complications increases.

Pills